DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.

[1]  J. Koeleman,et al.  Dynamics of Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and the Impact of Booster Vaccinations in Previously Infected and Infection-Naïve Individuals , 2022, Vaccines.

[2]  O. Launay,et al.  COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness , 2022, Viruses.

[3]  Md. Sahidul Islam,et al.  Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review , 2022, International journal of biological sciences.

[4]  M. Hinescu,et al.  Vaccine mRNA Can Be Detected in Blood at 15 Days Post-Vaccination , 2022, Biomedicines.

[5]  D. Barouch,et al.  Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5 , 2022, The New England journal of medicine.

[6]  Junfen Fan,et al.  COVID-19 vaccine development: milestones, lessons and prospects , 2022, Signal Transduction and Targeted Therapy.

[7]  F. Lattanzio,et al.  COVID-19 Vaccines: Current and Future Perspectives , 2022, Vaccines.

[8]  N. Dean,et al.  The changing epidemiology of SARS-CoV-2 , 2022, Science.

[9]  M. Z. Salleh,et al.  Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2 , 2022, PeerJ.

[10]  D. Zeng,et al.  Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina , 2022, The New England journal of medicine.

[11]  F. Caruso,et al.  Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine , 2022, medRxiv.

[12]  A. Haque,et al.  Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy , 2022, Journal of Autoimmunity.

[13]  D. Vaughn,et al.  Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 , 2021, npj Vaccines.

[14]  O. Kalinina,et al.  Imbalanced Immune Response of T-Cell and B-Cell Subsets in Patients with Moderate and Severe COVID-19 , 2021, Viruses.

[15]  C. Prudêncio,et al.  Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients , 2021, Scientific Reports.

[16]  P. Díaz,et al.  The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity , 2021, Frontiers in Immunology.

[17]  R. Langer,et al.  Lipid nanoparticles for mRNA delivery , 2021, Nature Reviews Materials.

[18]  E. Grundberg,et al.  Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals , 2021, BMC Medicine.

[19]  A. Marchant,et al.  Immunological mechanisms of vaccine-induced protection against COVID-19 in humans , 2021, Nature Reviews Immunology.

[20]  P. Kalra,et al.  Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine , 2021, The New England journal of medicine.

[21]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[22]  Qiu Sun,et al.  Antibodies and Vaccines Target RBD of SARS-CoV-2 , 2021, Frontiers in Molecular Biosciences.

[23]  A. Fiore-Gartland,et al.  Evidence for antibody as a protective correlate for COVID-19 vaccines , 2021, Vaccine.

[24]  A. Gulbake,et al.  COVID-19 vaccines: rapid development, implications, challenges and future prospects , 2021, Human Cell.

[25]  Yvette N. Lamb.  BNT162b2 mRNA COVID-19 Vaccine: First Approval , 2021, Drugs.

[26]  R. Jhaveri.  The COVID-19 mRNA Vaccines and the Pandemic: Do They Represent the Beginning of the End or the End of the Beginning? , 2021, Clinical Therapeutics.

[27]  Vaishali R. Moulton,et al.  Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? , 2021, Frontiers in Physiology.

[28]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[29]  M. Beltramello,et al.  Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.

[30]  Matthew S. Miller,et al.  Immunological considerations for COVID-19 vaccine strategies , 2020, Nature Reviews Immunology.

[31]  J. Mascola,et al.  SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.

[32]  J. Szebeni,et al.  Anti-PEG antibodies: Properties, formation and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. , 2020, Advanced drug delivery reviews.

[33]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[34]  Vineet D. Menachery,et al.  Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients , 2020, Cell Reports Medicine.

[35]  K. Loré,et al.  Imaging the early fate of mRNA vaccines , 2019, Nature Biomedical Engineering.

[36]  Kimberly J. Hassett,et al.  Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  Kimberly J. Hassett,et al.  Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  Da-yong Dong,et al.  Human IgG Subclasses against Enterovirus Type 71: Neutralization versus Antibody Dependent Enhancement of Infection , 2013, PloS one.

[39]  A. Bertoletti,et al.  Understanding the T cell immune response in SARS coronavirus infection , 2012, Emerging Microbes & Infections.

[40]  M. Farcet,et al.  Human IgG Subclasses: In Vitro Neutralization of and In Vivo Protection against West Nile Virus , 2010, Journal of Virology.

[41]  D. Scott,et al.  Immunoglobulin G3 from Polyclonal Human Immunodeficiency Virus (HIV) Immune Globulin Is More Potent than Other Subclasses in Neutralizing HIV Type 1 , 2001, Journal of Virology.

[42]  Y. Kawaoka,et al.  Development of an mRNA vaccine against COVID-19 , 2021, Translational and Regulatory Sciences.